Literature DB >> 35307596

Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis.

Colin Dunn1, Bo Lin2, Nicole E Rich1, Madhukar S Patel3, Purva Gopal2, Amit G Singal4.   

Abstract

Patients with cirrhosis are high risk for developing hepatocellular carcinoma (HCC) and warrant surveillance using abdominal ultrasound and α-fetoprotein.1 Those with positive surveillance results should undergo diagnostic evaluation with multiphase computed tomography (CT) or magnetic resonance imaging (MRI). The LI-RADS system is an evidence-based system to classify observations on CT or MRI in at-risk patients, ranging from LR-1 (definite benign) to LR-5 (definite HCC), with LR-3 and LR-4 observations being intermediate risk for HCC.2 LR-3 and LR-4 observations are observed on CT or MRI in more than one-fourth of patients undergoing HCC surveillance and have a high, yet variable, risk for progression to HCC.3 Approximately one-third of patients with LR-3 observations and more than two-thirds of LR-4 observations develop HCC, and surveillance strategies vary widely in practice.4,5 Variation in radiographic appearance and natural history of these observations suggests that this may be a heterogeneous group of patients; however, their histopathology has not been well described. Herein, we correlated imaging findings and explant histopathology from liver transplant recipients with at least 1 LR-3 or LR-4 observation on CT or MRI within 6 months preceding transplantation.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2022        PMID: 35307596      PMCID: PMC9481748          DOI: 10.1016/j.cgh.2022.03.009

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  9 in total

1.  Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program.

Authors:  Monica A Konerman; Aashesh Verma; Betty Zhao; Amit G Singal; Anna S Lok; Neehar D Parikh
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

Review 2.  Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma.

Authors:  An Tang; Amit G Singal; Donald G Mitchell; Elizabeth M Hecht; Kathryn J Fowler; Laura Kulik; Neehar D Parikh; Yuko Kono; Claude B Sirlin
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-13       Impact factor: 11.382

Review 3.  Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Emily Harding-Theobald; Jeremy Louissaint; Bharat Maraj; Edward Cuaresma; Whitney Townsend; Mishal Mendiratta-Lala; Amit G Singal; Grace L Su; Anna S Lok; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2021-08-12       Impact factor: 9.524

4.  Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging.

Authors:  Masahiro Tanabe; Akihiko Kanki; Tanya Wolfson; Eduardo A C Costa; Adrija Mamidipalli; Marilia P F D Ferreira; Cynthia Santillan; Michael S Middleton; Anthony C Gamst; Yuko Kono; Alexander Kuo; Claude B Sirlin
Journal:  Radiology       Date:  2016-04-26       Impact factor: 11.105

Review 5.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

6.  Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Erin Wolf; Nicole E Rich; Jorge A Marrero; Neehar D Parikh; Amit G Singal
Journal:  Hepatology       Date:  2020-11-20       Impact factor: 17.425

7.  A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

Authors:  Naoto Fujiwara; Masahiro Kobayashi; Austin J Fobar; Ayaka Hoshida; Cesia A Marquez; Bhuvaneswari Koneru; Gayatri Panda; Masataka Taguri; Tongqi Qian; Indu Raman; Quan-Zhen Li; Hiroki Hoshida; Hitomi Sezaki; Hiromitsu Kumada; Ryosuke Tateishi; Takeshi Yokoo; Adam C Yopp; Raymond T Chung; Bryan C Fuchs; Thomas F Baumert; Jorge A Marrero; Neehar D Parikh; Shijia Zhu; Amit G Singal; Yujin Hoshida
Journal:  Med (N Y)       Date:  2021-04-21

8.  Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis.

Authors:  Amit G Singal; Sruthi Patibandla; Joseph Obi; Hannah Fullington; Neehar D Parikh; Adam C Yopp; Jorge A Marrero
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-10       Impact factor: 13.576

9.  Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.

Authors:  Nicolas Goossens; Amit G Singal; Lindsay Y King; Karin L Andersson; Bryan C Fuchs; Cecilia Besa; Bachir Taouli; Raymond T Chung; Yujin Hoshida
Journal:  Clin Transl Gastroenterol       Date:  2017-06-22       Impact factor: 4.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.